Equities

Xeris Biopharma Holdings Inc

Xeris Biopharma Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.08
  • Today's Change0.035 / 1.15%
  • Shares traded468.73k
  • 1 Year change+76.72%
  • Beta1.8068
Data delayed at least 15 minutes, as of Nov 22 2024 20:02 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients’ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.

  • Revenue in USD (TTM)187.36m
  • Net income in USD-63.11m
  • Incorporated2021
  • Employees377.00
  • Location
    Xeris Biopharma Holdings Inc1375 West Fulton Street, Suite 1300CHICAGO 60607United StatesUSA
  • Phone+1 (302) 658-7581
  • Fax+1 (302) 655-5049
  • Websitehttps://www.xerispharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sanara Medtech Inc78.06m-8.36m326.44m107.00--8.20--4.18-0.9871-0.98719.244.550.95181.918.39729,503.40-10.33-17.73-12.37-22.0790.1688.08-10.86-17.132.02-3.440.4326--41.7761.9345.79--99.09--
Amylyx Pharmaceuticals Inc196.49m-259.47m355.76m384.00--1.81--1.81-3.82-3.822.872.860.54792.5612.64511,679.70-72.35---84.00--78.88---132.05--4.55--0.00--1,612.94--124.84------
Revance Therapeutics Inc247.00m-180.81m402.83m597.00------1.63-1.91-1.952.55-1.550.4971.036.71413,740.40-36.38-55.55-43.47-63.2072.61---73.20-304.963.05-15.401.58--76.55128.849.10---0.3022--
Aquestive Therapeutics Inc58.90m-35.19m411.21m135.00------6.98-0.4514-0.45140.7297-0.49820.69542.566.46436,296.30-41.55-76.63-54.06-123.8569.3964.24-59.75-102.955.91-2.72----6.09-5.5985.54---11.42--
Rigel Pharmaceuticals Inc157.47m3.88m441.08m147.00115.56--76.072.800.21670.21678.98-0.8311.243.065.821,071,252.003.05-28.825.10-47.2689.4397.882.46-35.761.871.691.32---2.7921.3057.16--68.45--
SIGA Technologies Inc173.73m85.71m447.49m45.005.282.645.192.581.191.192.422.370.98230.503417.253,860,698.0048.4622.3457.0127.5681.6088.6549.3341.145.32--0.0029.5126.31-21.75100.76-30.57-26.67--
Xeris Biopharma Holdings Inc187.36m-63.11m452.96m377.00------2.42-0.4388-0.43881.30-0.19010.57750.83894.30496,978.80-19.45-43.60-26.81-56.5781.3678.23-33.69-143.081.29-1.861.14--48.68131.5034.23--8.43--
Theravance Biopharma Inc63.19m-49.40m470.14m99.00--2.55--7.44-1.01-1.011.293.780.1642--3.73638,303.00-12.84-40.51-13.71-48.50-----78.18-305.27----0.1379--11.84-0.995640.54---19.24--
Esperion Therapeutics Inc295.45m-86.77m486.68m240.00------1.65-0.6585-0.65851.72-1.891.100.82755.351,231,046.00-32.41-69.45-74.85-101.8181.58---29.37-147.441.370.3253----54.14--10.45------
Zevra Therapeutics Inc24.79m-84.93m487.32m65.00--6.97--19.66-1.96-1.960.58251.310.150--2.80381,323.10-51.39-32.11-61.91-39.8953.72---342.63-128.42---25.930.4578--170.26---72.00--69.75--
Emergent Biosolutions Inc1.13bn-208.80m509.33m1.60k--1.00--0.4525-4.10-4.1021.199.400.66782.216.66703,437.50-12.39-2.94-16.86-3.6633.5153.24-18.55-5.951.47-1.200.5658---6.106.05-259.40---4.29--
SNDL Inc652.27m-79.06m525.69m2.52k--0.6076--0.8059-0.3017-0.30172.483.260.60624.9836.38259,248.20-7.61-24.44-8.22-27.9425.6922.49-12.55-62.174.16--0.114--27.63--49.83------
ASP Isotopes Inc2.30m-27.05m548.67m76.00--36.50--239.00-0.628-0.6280.05490.21120.068----30,206.32-71.81---89.44--36.54---1,055.85-----8.110.6748-------229.34------
Eyepoint Pharmaceuticals Inc45.71m-103.57m568.60m121.00--2.04--12.44-2.01-2.010.90184.090.19831.05106.19377,793.40-44.94-40.44-59.48-47.7991.4883.45-226.57-186.235.45--0.00--11.14--30.77------
CorMedix Inc12.26m-46.15m626.80m82.00--10.18--51.12-0.8011-0.80110.2121.010.1451----149,539.50-54.61-54.84-64.60-62.3283.576.18-376.35-18,323.423.60--0.00---100.00---56.02--46.27--
Data as of Nov 22 2024. Currency figures normalised to Xeris Biopharma Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

27.23%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 20249.61m6.45%
The Vanguard Group, Inc.as of 30 Sep 20247.49m5.03%
Caxton Corp.as of 30 Sep 20245.11m3.43%
CenterBook Partners LPas of 30 Sep 20243.48m2.34%
Geode Capital Management LLCas of 30 Sep 20243.33m2.24%
SSgA Funds Management, Inc.as of 30 Sep 20243.20m2.15%
Rosalind Advisors, Inc.as of 30 Sep 20243.10m2.08%
AIGH Capital Management LLCas of 30 Sep 20242.19m1.47%
Renaissance Technologies LLCas of 30 Sep 20241.60m1.07%
Millennium Management LLCas of 30 Sep 20241.45m0.97%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.